Evidence map›Paper›PMID 39484056›Full record

ArticleOral oncology reports2024

Clinicopathological risk factors of oral second primary tumours.

Jelena Karan, Miriam P Rosin, Lewei Zhang, Denise M Laronde

Abstract read
In one paragraph

Article in Oral oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jelena KaranFaculty of Dentistry, University of British Columbia, 2199 Wesbrook Mall, Vancouver, BC, Canada, V6T1Z3.
Miriam P RosinCancer Control Research, British Columbia Cancer Agency, 675 W10th Avenue, Vancouver, BC, Canada, V5Z 1L3.
Lewei ZhangFaculty of Dentistry, University of British Columbia, 2199 Wesbrook Mall, Vancouver, BC, Canada, V6T1Z3.
Denise M LarondeFaculty of Dentistry, University of British Columbia, 2199 Wesbrook Mall, Vancouver, BC, Canada, V6T1Z3.

Funding

CLONAL CHANGES IN ORAL LESIONS OF HIGH-RISK PATIENTSR01DE013124 · NIDCR · BRITISH COLUMBIA CANCER AGENCY · PI ROSIN, MIRIAM P. · 1999 to 2007
$2.1M
Optical Techniques and Oral Precancer ManagementR01DE017013 · NIDCR · BRITISH COLUMBIA CANCER AGENCY · PI ROSIN, MIRIAM P. · 2005 to 2009
$1.9M
NIDCR NIH HHS R01 DE013124NIDCR NIH HHS R01 DE017013
6 · The paper itself

Abstract

Background: Oral second primary tumours (SPTs) have a poor prognosis due to late-stage diagnosis. This study evaluates the demographic and clinicopathological risk predictors of SPTs. Methods: Patients with oral squamous cell carcinoma, carcinoma in situ, or severe dysplasia were accrued into the Oral Cancer Prediction Longitudinal study within one year post-curative treatment. Data on demographics, risk habits, and primary tumour characteristics were collected. Clinical follow-up included assessing the presence of second oral premalignant lesions (SOPLs), clinicopathological features, and the results from toluidine blue staining and fluorescence visualization. Results: Among 296 patients, 23 (8 %) developed SPTs. Older age at primary cancer diagnosis (P = 0.008) and a history of chewing tobacco or betel nut (P = 0.043) increased the risk of SPTs. Patients with primary tumours located at low-risk sites had an increased risk of SPTs (P = 0.004), which often presented at high-risk sites. The presence of SOPLs (P < 0.001), and multiple lesions (P = 0.017) significantly increased the risk of SPTs. Positive toluidine blue staining indicated a trend toward higher risk of SPTs, whereas fluorescence visualization did not. The median time to SPT diagnosis was 3.25 years post-treatment. Conclusions: Identifying second or multiple oral premalignant lesions is critical for predicting the risk of SPTs regardless of their clinical or histological characteristics. Routine biopsy of these lesions should be prioritized to ensure timely diagnosis. Incorporating these risk predictors into clinical follow-up can enhance early cancer detection and improve patient outcomes.

Indexed as

Betel nutBiopsyHead and neck cancerOral cancerRisk factorsSecond primary cancerSquamous cell carcinomaTobacco useToluidine blue

Identifiers

PMID39484056
PMCPMC11526299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.